Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone: Treatment‐related mortality
Cytarabine plus high‐dose methotrexate showed no clear difference in treatment‐related mortality compared with high‐dose methotrexate alone (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone Treatment‐related mortality · patients with primary CNS lymphoma Cytarabine plus high‐dose methotrexate showed no clear difference in treatment‐related mortality compared with high‐dose methotrexate alone (moderate certainty). Role of chemotherapy additional to high‐dose methotrexate for primary central nervous system lymphoma (PCNSL) (2012) · Cochrane Headline outcomes only | RR 3.08 [0.33, 28.32] | 1 study · 79 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Role of chemotherapy additional to high‐dose methotrexate for primary central nervous system lymphoma (PCNSL) 2012 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.